Table 4.
ATC group | OR* (95% CI) | 122 cases n (%) | 708 controls n (%) |
---|---|---|---|
Alimentary tract and metabolism (A) | |||
Pantoprazole | 1.04 (0.4, 2.3) | 18 (14.8) | 47 (6.6) |
Metoclopramide | 2.4 (0.5, 9.1) | 6 (4.9) | 10 (1.4) |
Magnesium | 0.3 (0.1, 0.9) | 4 (3.3) | 60 (8.5) |
Blood and blood forming organs (B) | |||
Phenprocoumon | 3.3 (1.5, 6.7) | 16 (13.1) | 39 (5.5) |
Enoxaparin | 4.5 (0.5, 46.7) | 3 (2.5) | 2 (0.3) |
Acetylsalicylic acid | 0.3 (0.1, 0.7) | 9 (7.4) | 133 (18.8) |
Cardiovascular system (C) | |||
Bisoprolol + hydrochlorothiazide | 13.1 (1.0, 149.3) | 4 (3.3) | 2 (0.3) |
Lisinopril | 3.9 (0.8, 15.6) | 5 (4.1) | 7 (1.0) |
Irbesartan | 25.0 (1.6, 701.5) | 3 (2.5) | 1 (0.1) |
Systemic hormonal preparations (G/H) | |||
Combined oral contraceptives | 1.1 (0.1, 5.2) | 11 (9.0) | 19 (2.7) |
Oestrogen + levonogestrel | 2.8 (0.3, 36.0) | 5 (4.1) | 6 (0.8) |
Oestrogen + dienogest | 13.2 (1.2, 218.6) | 4 (3.3) | 2 (0.3) |
Glucocorticoids | 1.8 (0.7, 4.1) | 17 (13.9) | 46 (6.5) |
Dexamethasone | 9.3 (0.8, 225.6) | 4 (3.3) | 1 (0.1) |
Antiinfectives (J) | |||
Antibiotics | 1.3 (0.2, 5.2) | 17 (13.9) | 26 (3.7) |
Macrolides | 0.3 (0.01, 7.3) | 6 (4.9) | 3 (0.4) |
Clarithromycin | 30.2 (1.2, >999.9) | 4 (3.3) | 1 (0.1) |
Beta-lactam antibiotics | 2.4 (0.3, 20.9) | 9 (7.4) | 12 (1.7) |
Fluoroquinolones | 21.0 (1.2, 634.9) | 5 (4.1) | 3 (0.4) |
Ciprofloxacin | 0.3 (0.01, 10.4) | 3 (2.5) | 2 (0.3) |
Rifampicin | 6.7 (0.1, 350.3) | 2 (1.6) | 1 (0.1) |
Ethambutol + pyrazinamide | 14.1 (0.8, 392.0) | 3 (2.5) | 1 (0.1) |
Aciclovir | 3.3 (0.2, 40.4) | 3 (2.5) | 2 (0.3) |
Musculo-skeletal and nervous system (M/N) | |||
Ibuprofen | 1.3 (0.5, 2.9) | 15 (12.3) | 43 (6.1) |
Metamizole | 5.2 (2.0, 13.4) | 13 (10.7) | 14 (2.0) |
Flupirtine | 40.2 (5.5, 856.9) | 8 (6.6) | 1 (0.1) |
Valerian radix | 5.3 (0.98, 27.3) | 5 (4.1) | 4 (0.6) |
Antidepressants | 0.9 (0.3, 2.5) | 15 (12.3) | 40 (5.6) |
Amitriptyline | 0.9 (0.1, 9.0) | 4 (3.3) | 5 (0.7) |
Citalopram | 7.1 (1.2, 44.1) | 6 (4.9) | 7 (1.0) |
Various | |||
Terbinafine | 20.1 (1.9, 440.4) | 2 (1.6) | 1 (0.1) |
Cough and cold preparations | 1.8 (0.2, 20.4) | 4 (3.3) | 4 (0.6) |
Mucolytics | 2.3 (0.4, 8.9) | 7 (5.7) | 15 (2.1) |
Hypromellose | 8.9 (0.9, 92.7) | 3 (2.5) | 2 (0.3) |
Joint drug assessment (adjusted for age, gender and all drugs with a significant OR in single drug assessment, i.e. all drugs illustrated in Table 4).